{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:44:19Z","timestamp":1792651459096,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.10.064","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T09:20:18Z","timestamp":1572945618000},"page":"530-538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14\u202fweeks and 9\u202fmonths of age"],"prefix":"10.1016","volume":"38","author":[{"given":"Lulu C.","family":"Bravo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina C.","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvacion R.","family":"Gatchalian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Emmeline B.","family":"Montellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa Fay Corazon B.","family":"Tabora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Thierry-Carstensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille Nyholm","family":"Tingskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Wachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-2001","authenticated-orcid":false,"given":"Ananda S.","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille Ingemann","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Vestergaard","family":"Kusk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.10.064_b0005","unstructured":"World Health Organization (WHO). Poliomyelitis.. 2019. Accessed 27Mar2019. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/poliomyelitis."},{"key":"10.1016\/j.vaccine.2019.10.064_b0010","unstructured":"World Health Organization (WHO). Polio eradication & endgame strategic plan 2013-2018. Geneva, Switzerland. WHO Press World Health Organization; 2013. Accessed 27Mar2019. http:\/\/polioeradicationorg\/who-we-are\/strategy\/."},{"key":"10.1016\/j.vaccine.2019.10.064_b0015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.coviro.2013.05.007","article-title":"Poliovirus vaccination options for achieving eradication and securing the endgame","volume":"3","author":"Estivariz","year":"2013","journal-title":"Current Opin Virol"},{"key":"10.1016\/j.vaccine.2019.10.064_b0025","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.vaccine.2015.02.011","article-title":"Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats","volume":"33","author":"Andreasen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.vaccine.2016.12.027","volume":"35","author":"Lindgren","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0035","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1473-3099(17)30177-9","volume":"17","author":"Rivera","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.064_b0040","unstructured":"Robertson S. Module 6: Poliomyelitis. In: The Immunological Basis for Immunization Series, WHO. 1993. Accessed 27Mar2019. http:\/\/www.who.int\/ihr\/polio1993en.pdf."},{"key":"10.1016\/j.vaccine.2019.10.064_b0045","series-title":"II Serological Studies and Virus Isolations from Pharyngeal Secretions","first-page":"71","article-title":"The effect of gamma globulin on subclinical infection in familial associates of poliomyelitis cases","author":"Brown","year":"1955"},{"key":"10.1016\/j.vaccine.2019.10.064_b0050","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.10.064_b0055","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-45.","DOI":"10.1001\/jama.284.23.3043"},{"key":"10.1016\/j.vaccine.2019.10.064_b0060","unstructured":"International Conference on Harmonisation. ICH Harmonised guideline. Integrated addendum to ICH E6(1): guideline for good clinical practice E6(R2). 2016. Accessed 27Mar2019. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R2__Step_4_2016_1109.pdf."},{"key":"10.1016\/j.vaccine.2019.10.064_b0065","doi-asserted-by":"crossref","unstructured":"Melnick JL. Enteroviruses. In: AS E, editor. Viral infections of humans: Epidemiology and control. Switzerland: Springer Nature; 1984. p. 187-251.","DOI":"10.1007\/978-1-4684-4727-9_9"},{"key":"10.1016\/j.vaccine.2019.10.064_b0070","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.vaccine.2015.01.072","article-title":"Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials","volume":"33","author":"Donken","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2019.10.064_b0075","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa0800390","article-title":"Monovalent type 1 oral poliovirus vaccine in newborns","volume":"359","author":"El-Sayed","year":"2008","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2019.10.064_b0080","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2019.10.064_b0085","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1016\/j.vaccine.2008.07.033","article-title":"Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age","volume":"26","author":"Pietrzyk","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0090","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/651611","article-title":"Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba","volume":"201","author":"Resik","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.064_b0095","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2015.07.085","article-title":"Maternal antibodies and infant immune responses to vaccines","volume":"33","author":"Edwards","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapediatrics.2017.0638","article-title":"The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses : an individual participant meta-analysis","volume":"171","author":"Voysey","year":"2017","journal-title":"JAMA Pediatrics"},{"key":"10.1016\/j.vaccine.2019.10.064_b0105","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/j.ijid.2011.10.002","article-title":"Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines","volume":"16","author":"Cadorna-Carlos","year":"2012","journal-title":"Int J Infect Dis Off Publicat Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.064_b0110","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1093\/infdis\/jix038","article-title":"Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose-sparing option for polio immunization","volume":"216","author":"Okayasu","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.10.064_b0115","doi-asserted-by":"crossref","unstructured":"Vidor E. Poliovirus vaccine - inactivated. Vaccines. 7th ed: Elsevier; 2018. p. 841-65.","DOI":"10.1016\/B978-0-323-35761-6.00047-X"},{"key":"10.1016\/j.vaccine.2019.10.064_b0120","unstructured":"Hickling J, Jones R, Nundy N. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries: An economic analysis of strategies to reduce the cost of routine IPV immunization 2010. Report. Accessed 27Mar2019. https:\/\/path.azureedge.net\/media\/documents\/TS_IPV_econ_analysis.pdf."},{"key":"10.1016\/j.vaccine.2019.10.064_b0125","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/erv.11.72","article-title":"A DTaP-IPV\/\/PRP approximately T vaccine (Pentaxim): a review of 16 years' clinical experience","volume":"10","author":"Plotkin","year":"2011","journal-title":"Expert Rev Vacc."},{"key":"10.1016\/j.vaccine.2019.10.064_b0130","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.vaccine.2003.09.011","article-title":"Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells","volume":"22","author":"Haastrup","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0135","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1016\/j.vaccine.2013.08.034","article-title":"Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults\u2013a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience","volume":"31","author":"Thierry-Carstensen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0140","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1016\/j.vaccine.2012.06.073","volume":"30","author":"Thierry-Carstensen","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0145","doi-asserted-by":"crossref","first-page":"6971","DOI":"10.1016\/j.vaccine.2012.09.059","article-title":"Adjuvants and inactivated polio vaccine: a systematic review","volume":"30","author":"Hawken","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.10.064_b0150","unstructured":"Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). 2016;388:1725-74."},{"key":"10.1016\/j.vaccine.2019.10.064_b0155","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19314446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:39:16Z","timestamp":1759401556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19314446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X19314446"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14\u202fweeks and 9\u202fmonths of age","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}